Member Info for Laura2022

Hi msuk

How do this....can you tell they are doing it

Thanks

L

Must have been purchased

When released could be a game changer

Purchased £5000 more just now

Fantastic Trench

I am trying to purchase some more at 2.1p but there is none available

Had to settle for £7k but will be adding more

You can sell lots but cannot buy for last 20mins

Yes..cannot buy

29p

S we saw with POS ( 1000% up in 8 weeks) things cam change quickly Brighty

80p or more is being suggested

Great

Now 20% up from my 14p buys

FCS will also be q big mover

Usual metrics would be at least 2 or 3 times annual revenues,and cyber companies OSI and EISC went for higher multiples I think

So the current £1.5mln value of FCS business is too low

year ended 31 March 2023 ("FY23"). 

Total revenues for FY23 are expected to be c.£3.8m (2022: c.£3.5m) representing organic growth of c.9% year on year. The Group experienced steady growth on PenTest revenues of 5% and it also saw strong growth in SOC monitoring revenues which grew by c.21% when compared to FY22. Total SOC order values (New Logo, Renewals, Uplifts & extensions) were up by 58% on FY22, reflecting the continual achievement of service excellence (with a strong Net Promoter Score of 80%+). This resulted in a growing volume of SOC clients through high annual renewal levels as well as growth in the estate coverage of individual clien

It's gone from 10k to 20k and now to 50k shares today

Loosk like there is a buyer in the background

On Telegram peple are saying a company called CNS are looking to buy FCS for over £5mln

Going well

PYC tool I'll be useful no that testing has become national and international news

Great for OBD and PYC in this fight against prostate cancer

Great to see this contine everyone

This was from OBD today

Noticed the precision medicine yet again at the forefront

UK immediate access

The PSE test will be immediately available to men in the UK using the US testing facility to process results initially. OBD is in the process of obtaining ISO15189 certification for a clinical lab within its Oxford, UK laboratory. Once certified, expected early in 2024, PRECISION MEDICINE TESTS( my capitals fyi), like EpiSwitch PSE, will be run there - shortening the overall turnaround time for results.

More information may be found at www.94percent.com. Please contact Oxford BioDynamics client services anytime by emailing the team at  pse.test@myobdx.com.

"There is a clear need in everyday clinical practice for a much more accurate blood test that can screen men for prostate cancer and accurately identify those at risk, while sparing those who up to now would be subject to unnecessary, expensive, and invasive procedures. It feels wholly appropriate that the early launch of the test coincides with Prostate Cancer Awareness month," said Dr Jon Burrows, OBD's Chief Executive Officer. "With the news today of the launch of another EpiSwitch-based product, we are continuing to improve patient health whilst also reducing the cost of care." 

My pleasure Acker

L